BiotechTube

HSPPC-96 or Oncophage

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malignant Melanoma

Conditions

Malignant Melanoma

Trial Timeline

Mar 1, 2002 → Dec 1, 2005

NCT ID
NCT00039000

About HSPPC-96 or Oncophage

HSPPC-96 or Oncophage is a phase 3 stage product being developed by Agenus for Malignant Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00039000. Target conditions include Malignant Melanoma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00039000Phase 3Completed

Competing Products

20 competing products in Malignant Melanoma

See all competitors
ProductCompanyStageHype Score
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabCSPC Pharmaceutical Group LimitedPhase 1/2
40
Fulvestrant + AbemaciclibEli LillyPhase 2
52
Tadalafil + GemcitabineEli LillyPhase 1
33
Patritumab DeruxtecanDaiichi SankyoPhase 1/2
41
Tivantinib + FOLFOXDaiichi SankyoPhase 1/2
41
DS-1123Daiichi SankyoPhase 1
33
DS-8201aDaiichi SankyoPhase 1
33
DS-5573aDaiichi SankyoPhase 1
33
DS-6051bDaiichi SankyoPhase 1
33
U3-1565Daiichi SankyoPhase 1
33
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue MedicationsDaiichi SankyoPhase 1/2
41
DS-3201b + DS-3201bDaiichi SankyoPhase 1
33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kgDaiichi SankyoPhase 1
33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
41
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
CP-461Astellas PharmaPhase 2
52
enfortumab vedotinAstellas PharmaPhase 1
33
LNF1901 Monoclonal Antibody InjectionSun PharmaceuticalPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
41
Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
77

Other Products from Agenus

autologous human tumor-derived HSPPC-96Phase 3
69
HSPPC-96Phase 3
69
Balstilimab + Botensilimab + Folfox Protocol + XELOX + NivolumabPhase 3
69
Balstilimab + BotensilimabPhase 3
69
Balstilimab (BAL) + Topotecan + Vinorelbine + Gemcitabine + Irinotecan + PemetrexedPhase 3
69